A Multidisciplinary Approach to CAR T-cell Therapy for Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Episode 10
Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL
Experts discuss their combined experience with cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and other immunotoxicities post chimeric antigen receptor (CAR) T-cell therapy, whether Moffitt Cancer Center implements a standardized protocol to address and resolve cell therapy–associated immunotoxicities, how interventions are modified across grades of severity, and the use of prophylactic strategies to mitigate treatment-related adverse events as well as the roles of the multidisciplinary team in patient monitoring during the initial 30 days and the longer-term postinfusion period.
Video content above is prompted by the following:
In general, what has been your combined experience with CRS, ICANS, and other immunotoxicities post CAR T-cell therapy?
At Moffitt Cancer Center, do you implement a standardized protocol to address and resolve cell therapy–associated immunotoxicities and adverse events?
- How do you modify your interventions across grades of severity?
- Do you employ any prophylactic mitigation strategies before or during CAR T-cell infusion to attenuate the risk and/or severity of treatment-related adverse events?
- At your center, who on the multidisciplinary team participates in patient monitoring during the initial 30 days post CAR T-cell therapy?
- How is the patient monitored and who monitors them during the longer-term postinfusion period?
Related Content:
